GlassScriptPhysician profile
Laurey Robin Hanselman
NPI 1033106372
$6,007.84
in general payments reported to CMS, 2019-2025
42 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $128 · 2021: $353 · 2022: $1,164 · 2023: $1,300 · 2024: $1,315 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,648 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,647.78 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $927.39 | 2021-2025 | |
| Novo Nordisk INC | $836.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $541.04 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $371.89 | 2020-2025 | Rexulti |
| Amgen INC. | $360.81 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $327.25 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $289.90 | 2019-2025 | Spravato |
| Pfizer INC. | $284.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $197.46 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Astrazeneca Pharmaceuticals LP | $156.36 | 2019-2025 | Airsupra |
| Horizon Therapeutics Plc | $145.40 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $116.13 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $116.04 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $86.53 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $85.64 | 2021-2023 | Livalo, Seglentis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurey Hanselman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.